Chad  Patterson net worth and biography

Chad Patterson Biography and Net Worth

Chief Commercial Officer of iRhythm Technologies

Chad Patterson has served as our Chief Commercial Officer since July 2022.  From January 2021 to July 2022, Mr. Patterson served as Executive Vice President, Chief Marketing Officer at DexCom, Inc., a company that develops, manufactures, produces and distributes continuous glucose monitoring systems for diabetes management. Mr. Patterson previously served in roles of increasing seniority at DexCom, including as Senior Vice President, Global Marketing and Product Management from March 2020 to January 2021, Vice President, Global Marketing and Product Management from March 2019 to March 2020, Senior Director, Global Consumer Marketing from March 2018 to March 2019, and Director of Marketing from November 2015 to February 2018. Prior to joining DexCom, Mr. Patterson held various positions at Nestlé, a manufacturer of food products, from 2005 to 2015.

Mr. Patterson has a B.A in Marketing, Entrepreneurship, and International Business from Gonzaga University and an M.B.A. from the University of Southern California, Marshall School of Business.

What is Chad Patterson's net worth?

The estimated net worth of Chad Patterson is at least $3.38 million as of August 2nd, 2024. Mr. Patterson owns 37,133 shares of iRhythm Technologies stock worth more than $3,379,474 as of November 6th. This net worth estimate does not reflect any other investments that Mr. Patterson may own. Additionally, Mr. Patterson receives a salary of $836,550.00 as Chief Commercial Officer at iRhythm Technologies. Learn More about Chad Patterson's net worth.

How old is Chad Patterson?

Mr. Patterson is currently 42 years old. There are 6 older executives and no younger executives at iRhythm Technologies. The oldest executive at iRhythm Technologies is Mr. Marc Rosenbaum, Senior VP of Finance & Chief Accounting Officer, who is 52 years old. Learn More on Chad Patterson's age.

What is Chad Patterson's salary?

As the Chief Commercial Officer of iRhythm Technologies, Inc., Mr. Patterson earns $836,550.00 per year. The highest earning executive at iRhythm Technologies is Mr. Quentin S. Blackford, President, CEO & Director, who commands a salary of $1,420,000.00 per year. Learn More on Chad Patterson's salary.

How do I contact Chad Patterson?

The corporate mailing address for Mr. Patterson and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Chad Patterson's contact information.

Has Chad Patterson been buying or selling shares of iRhythm Technologies?

Chad Patterson has not been actively trading shares of iRhythm Technologies over the course of the past ninety days. Most recently, Chad Patterson sold 3,012 shares of the business's stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $74.66, for a transaction totalling $224,875.92. Following the completion of the sale, the insider now directly owns 37,133 shares of the company's stock, valued at $2,772,349.78. Learn More on Chad Patterson's trading history.

Who are iRhythm Technologies' active insiders?

iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.

Are insiders buying or selling shares of iRhythm Technologies?

In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 12 times. They sold a total of 66,532 shares worth more than $6,937,400.34. The most recent insider tranaction occured on November, 4th when Director Abhijit Y Talwalkar bought 6,664 shares worth more than $500,866.24. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.

Information on this page was last updated on 11/4/2024.

Chad Patterson Insider Trading History at iRhythm Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2024Sell3,012$74.66$224,875.9237,133View SEC Filing Icon  
5/31/2024Buy280$74.98$20,994.4040,145View SEC Filing Icon  
See Full Table

Chad Patterson Buying and Selling Activity at iRhythm Technologies

This chart shows Chad Patterson's buying and selling at iRhythm Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iRhythm Technologies Company Overview

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $88.77
Low: $87.29
High: $91.61

50 Day Range

MA: $69.85
Low: $57.07
High: $86.68

2 Week Range

Now: $88.77
Low: $55.92
High: $124.11

Volume

300,080 shs

Average Volume

474,729 shs

Market Capitalization

$2.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23